Update on taxane development: new analogs and new formulations

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Taxanes, including paclitaxel and docetaxel, are vital antineoplastic agents targeting microtubule function.
• Traditional taxanes face challenges like poor solubility, dose-limiting toxicities, and drug resistance, often linked to their solvents (Cremophor EL, polysorbate 80).

Purpose of the Study:

• To review preclinical and clinical data on novel taxane formulations and analogs for solid tumor malignancies.
• To assess the clinical success and FDA approval status of new taxane agents.

Main Methods:

• Review of preclinical and clinical data.
• Analysis of FDA-approved and investigational taxane compounds.
• Comparison with emerging non-taxane microtubule inhibitors.

Main Results:

• Nab-paclitaxel and cabazitaxel are FDA-approved novel taxanes with demonstrated clinical success.
• Several other novel taxane compounds are unlikely to progress to widespread clinical use.
• Emergence of non-taxane microtubule-targeting agents (epothilones, eribulin) may limit future taxane development.

Conclusions:

• Novel taxane formulations have addressed some limitations of traditional taxanes.
• The landscape of microtubule-targeting chemotherapy is evolving, with increasing competition from non-taxane agents.